Chronic tobacco use dramatically increases health burdens and financial costs. Limitations of current smoking cessation therapies indicate the need for improved molecular targets. The main addictive component of tobacco, nicotine, exerts its dependency effects via nicotinic acetylcholine receptors (nAChRs). Activation of the homomeric a7 nAChR reduces nicotine's rewarding properties in conditioned place preference (CPP) test and i.v. self-administration models, but the mechanism underlying these effects is unknown. Recently, the nuclear receptor peroxisome proliferator-activated receptor type-a (PPARa) has been implicated as a downstream signaling target of the a7 nAChR in ventral tegmental area dopamine cells. The present study investigated PPARa as a possible mediator of the effect of a7 nAChR activation in nicotine dependence. Our results demonstrate the PPARa antagonist GW6471 blocks actions of the a7 nAChR agonist PNU282987 on nicotine reward in an unbiased CPP test in male ICR adult mice. These findings suggests that a7 nAChR activation attenuates nicotine CPP in a PPARa-dependent manner.
Introduction
The homomeric a7 nicotinic acetylcholine receptor (nAChR) has unique features of high calcium permeability, rapid desensitization and low probability of channel opening (S egu ela et al., 1993; Williams et al., 2011) , and has been shown to play a role in cognition, inflammation, immunity and neuroprotection (Corradi and Bouzat, 2016) . Recent findings suggest this low-affinity a7 nAChR modulates nicotine reward and reinforcement in rodents (Brunzell and McIntosh, 2012; Harenza et al., 2014) . The a7 nAChR selective agonist PNU282987 infused locally into the nucleus accumbens (NAc) shell reduced intravenous (i.v.) self-administered nicotine in rats. In contrast, ArIB, an a7 selective nAChR antagonist, infused in the NAc increased nicotine intake (Brunzell and McIntosh, 2012) .
Similarly, the genetic deletion of a7 nAChRs in mice enhances nicotine reward as measured in the conditioned place preference (CPP) test, whereas a7 knock-in (producing mice heterozygous for a Leu250-to-Thr substitution in the channel domain of a7 subunit which creates a gain-of-function mutation) abolishes nicotine preference. In addition, the selective a7 agonist PHA-543613 blocked the development of nicotine CPP in mice (Harenza et al., 2014) . Attenuation of nicotine reward and reinforcement by a7 nAChR agonists seems to be associated with a decreased nicotineinduced dopaminergic transmission in the brain, as PNU282987 blocks nicotine-induced increased firing activity of the ventral tegmental area (VTA) dopamine neurons in rats (Melis et al., 2013) .
This important effect of a7 nAChR modulation of nicotine reward has prompted studies of the underlying mechanism. It has been suggested that a7 nAChR activation regulates VTA dopaminergic cells via the peroxisome proliferator activated receptor a (PPARa) in the rat. The a7 nAChR agonist PNU282987 induced synthesis of two fatty acid PPARa endogenous ligands, oleoylethanolamide (OEA) and palmitoylethanolamide (PEA) , that in turn activate PPARa and phosphorylate b2-containing nAChRs on dopamine neurons via a tyrosine kinase pathway (Melis et al., 2013) . These findings suggest a pathway by which a7 nAChR pharmacological stimulation indirectly inactivates b2-containing nAChRs via PPARa receptors. However, the above-noted study did not directly investigate this mechanism using a nicotine reward paradigm which is imperative because b2-containing nAChRs are required for nicotine reward (Picciotto et al., 1998; Walters et al., 2006) .
PPARa is a nuclear ligand-activated transcription factor that when activated, enhances transcription of various genes involved in modulating many peripheral physiological responses such as inflammation and lipolysis (Zhu et al., 2000) . Importantly, PPARas, which are located in brain regions associated with reward (Moreno et al., 2004; Plaza-Zabala et al., 2010; Smaga et al., 2014) , have been shown to modulate the rewarding properties of abused substances such as alcohol and nicotine (Bilbao et al., 2015; Melis et al., 2008) . Acute administration of PPARa agonists attenuates nicotine (Mascia et al., 2011; Muldoon et al., 2013; Panlilio et al., 2012) and alcohol reinforcement (Bilbao et al., 2015) , alcohol intake (Blednov et al., 2016a (Blednov et al., , 2016b and nicotine-induced dopamine firing in rodents (Melis et al., 2008) . For example clofibrate, a lipid-lowering agent and PPARa agonist (Staels et al., 1998) , was shown in rats to block acquisition of nicotine seeking, decrease nicotine i.v. selfadministration and block nicotine-induced dopamine release into the NAc shell (Panlilio et al., 2012) .
Therefore, we hypothesize that PPARa may serve as a downstream mediator of a7 nAChR activation in nicotine reward. To test this hypothesis the present study investigated the interaction of the a7 nAChR and PPARa in a preclinical mouse model of reward (nicotine CPP). Furthermore, we examined PPARa activation in nicotine CPP and nicotine withdrawal, a behavioral outcome not measured before in preclinical studies with PPARa activators. We compared effects of the selective and potent PPARa agonist WY-14643 (Lo Verme et al., 2005; Willson et al., 2000) with a commonly used lipid lowering fibrate medication that activates PPARa fenofibrate (Keating, 2011) . Results from these experiments may provide insight into the roles of a7 nAChR and PPARa in nicotine dependence.
Materials and methods

Animals
ICR male mice (8 weeks upon arrival; Harlan Laboratories, Indianapolis, IN) served as subjects. Mice were housed four per cage with ad libitum access to food and water on a 12-h light cycle in a humidity and temperature controlled vivarium that was approved by the Association for Assessment and Accreditation of Laboratory Animal Care. Experiments were performed during the light cycle and were approved by the Institutional Animal Care and Use Committee of Virginia Commonwealth University and followed the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals.
Drugs
(À)-Nicotine hydrogen tartrate [(À)-1-methyl-2-(3-pyridyl) pyrrolidine (þ)-bitartrate] and mecamylamine HCl (non-selective nAChR antagonist) were purchased from Sigma-Aldrich Inc. (St. Louis, MO, USA). PNU282987 (a7 nAChR agonist) and cocaine HCl were provided by the Drug Supply Program of the National Institute on Drug Abuse (Rockville, MD). Drugs were dissolved in physiological saline and administered systemically (s.c. for nicotine, mecamylamine, PNU282987 and i.p. for cocaine). Fenofibrate (PPARa agonist), WY-14643 (PPARa agonist), and GW6471 (PPARa antagonist) were purchased from Tocris (Minneapolis, MN) and dissolved in a mixture of 1:1:18 [1 vol ethanol/1 vol Emulphor-620 (Sanofi-Aventis, Bridgewater, NJ) and 18 vol saline] and administered i.p. Drug solutions were prepared in 10 ml solutions (i.e. 3 mg of drug in 10 ml of vehicle indicates 3 mg/kg dose). Freshly prepared solutions were injected at a total volume of 1 ml/100 g of body weight. Doses are expressed as the free base of the drug.
Nicotine and cocaine conditioned place preference studies
An unbiased CPP paradigm was performed as we previously described (Kota et al., 2007; Sanjakdar et al., 2015) . Briefly, the CPP apparatus consisted of three chambers in a linear arrangement (ENV3013; Med Associates, St Albans, VT). The external white and black chambers (20 Â 20 Â 20 cm each) differed in overall color and floor texture (white mesh or black rod), and were separated by a smaller gray chamber with a smooth PVC floor. Partitions could be removed to allow access from the gray chamber to the black and white chambers. On day 1 animals were confined to the middle chamber for a 5 min habituation and then allowed to freely move between all three chambers for 15 min. Time spent in each chamber was recorded and these data were used to populate groups of approximately equal bias in baseline chamber preference. Twentyminute conditioning sessions occurred twice a day (days 2e4). During conditioning sessions mice were confined to one of the larger chambers. The saline groups received saline in one large chamber in the morning and saline in the other large chamber in the afternoon. The nicotine group received nicotine in one large chamber and saline in the other large chamber. Treatments were counterbalanced to ensure some mice received the unconditioned stimulus in the morning and others received it in the afternoon. The nicotine-paired chamber was randomized across groups. Sessions were 4 h apart and were conducted by the same investigator. On test day (day 5) mice could access all chambers for 15 min in a drug free state. The preference score was calculated by determining the difference between time spent in the drug paired side on the test day versus the time in drug paired side on the baseline day. Any mouse showing preference for one side higher than 65% was not used in the study.
Nicotine precipitated withdrawal studies
A well-established and validated nicotine withdrawal model was performed (Bagdas et al., 2014; Damaj et al., 2003; Muldoon et al., 2015; Salas et al., 2007) Mice were infused with 24 mg/kg/ day nicotine or saline for 14 days using s.c. osmotic minipumps (model 2000; Alzet Corporation, Cupertino, CA) implanted under isoflurane anesthesia (Jackson et al., 2008) . Nicotine concentration was adjusted according to animal weight and mini pump flow rate. On the morning of day 15 mice were pretreated with vehicle, WY-14643 (0.3, 1 and 5 mg/kg, i.p.; 15 min prior) or fenofibrate (50 and 100 mg/kg, i.p.; 1 h prior) before challenge with the non-selective nAChR antagonist mecamylamine (2 mg/kg; s.c.) to precipitate withdrawal. Affective (anxiety-like behavior) and physical (somatic signs and hyperalgesia) nicotine withdrawal signs were evaluated 10 min later as described in (Jackson et al., 2008) . Mice were first evaluated for 5 min in the elevated plus maze test for anxietyrelated behavior. Time spent on the open arms of the plus maze was used as a measure of anxiety-related response. The number of crosses between open and closed arms was counted as a measure of locomotor activity. The plus maze assessment was immediately followed by a 20 min observation of somatic signs measured as paw and body tremors, head shakes, backing, jumps, curls and ptosis. Mice were placed in clear activity cages without bedding for the observation period. The total number of somatic signs was tallied for each mouse and the average number of somatic signs during the observation period was plotted for each test group. Hyperalgesia was evaluated using the hot plate test immediately following the somatic sign observation period. Mice were placed into a 10-cm wide glass cylinder on a hot plate (Thermojust Apparatus, Richmond, VA) maintained at 52 C. The latency to reaction time (jumping or paw licking) was recorded. The specific testing sequence was chosen based on our prior studies showing that this order of testing reduced within-group variability and produced the most consistent results (Jackson et al., 2008) . All studies were performed by an observer blinded to experimental treatment.
Statistical analysis
Data were analyzed using the GraphPad software version 6.0 (GraphPad Software, Inc., La Jolla, CA) and expressed as the mean ± S.E.M. To determine if there was a nicotine effect (CPP and withdrawal studies), results with the nicotine control treatment groups were compared to the saline treatment groups with an unpaired two-tailed t-test. To determine if drugs given to alter/ block the effects of nicotine (PNU282987, GW6471, WY14643, and fenofibrate) had an effect on their own, treatment groups were compared to their appropriate vehicle treatment groups with an unpaired two-tailed t-test or ordinary one-way analysis of variance (ANOVA) where applicable. To determine whether treatment with the above-mentioned compounds affected nicotine CPP or precipitated nicotine withdrawal, results with the dosage groups (i.e. fenofibrate þ nicotine) were compared to the vehicle þ nicotine treatment group using HolmSíd ak comparison tests in conjunction with an ANOVA (in which the vehicle and i.e. fenofibrate þ vehicle groups were excluded). Two-way ANOVA followed by the Tukey multiple comparisons test was used in order to evaluate attenuation of dose response of nicotine CPP by PPARa agonist WY-14643. Comparisons were considered statistically significant when p < 0.05.
Results
Development of nicotine CPP attenuated by a7 nAChR full agonist PNU282987
Mice were conditioned with either saline or nicotine (0.5 mg/kg; s.c.) for 3 days in the CPP paradigm. The 0.5 mg/kg dose of nicotine has been previously shown to produce a significant preference in the CPP test (Grabus et al., 2006; Walters et al., 2006) . In Fig. 1 a robust CPP was observed in nicotineeconditioned mice pre-treated with vehicle (t ¼ 14.86, df ¼ 13, p < 0.05). PNU282987 given 15 min prior to nicotine, reduced nicotine reward in a dose-related manner [F (2, 21) ¼ 18.27, p < 0.0001]. As revealed by the HolmSíd ak comparison tests, PNU282987 (3 mg/kg) significantly altered nicotine CPP (p < 0.05), but was ineffective at the lower dose of 0.6 mg/kg (p > 0.05). PNU282987 at the dose of 3 mg/kg did not produce a preference in saline treated-mice (t ¼ 0.03760, df ¼ 12, p > 0.05).
PPARa antagonist blocks a7 nAChR agonist PNU282987 in nicotine CPP
The PPARa antagonist GW6471 was utilized to evaluate the PPARa dependency of a7 nAChR activation in nicotine CPP. In Fig. 2 male ICR mice conditioned with 0.5 mg/kg s.c. of nicotine for three days exhibited a significant preference (t ¼ 5.796, df ¼ 14, p < 0.05).
One-way ANOVA revealed that pretreatment with the a7 nAChR agonist PNU282987 (3 mg/kg; s.c.) given 15 min prior to nicotine attenuated nicotine CPP. This attenuation was significantly blocked by the PPARa antagonist GW6471 (2 mg/kg; i.p) administered 30 min prior to PNU282987 [F (3, 28) ¼ 6.301, p ¼ 0.0021], whereas GW6471 did not have an effect on nicotine CPP (p > 0.05). PNU282987 and GW6471 did not cause aversion or preference on their own or in combination [F (3, 24) 
The PPARa agonist WY-14643 attenuated nicotine CPP
We then tested the impact of direct activation of PPARa using the selective and potent PPARa agonist WY-14643 on nicotine CPP. Mice were conditioned with either saline or nicotine (0.5 mg/kg) for 3 days in the CPP paradigm. In Fig. 3A a robust CPP was observed Fig. 3B nicotine preference was significant at 0.5 and 1 mg/kg doses after 3 days of conditioning (p < 0.001). WY-14643 pretreatment significantly attenuated nicotine preference at 0.5 and 1 mg/kg (p < 0.05) and had no effect on the 0.1 mg/kg dose of nicotine (p > 0.05) WY-14643 did not produce preference or aversion on its own (p > 0.05).
PPARa agonist WY-14643 did not attenuate cocaine CPP
To test for the behavioral selectivity of WY-14643 on nicotine CPP, WY-14643 was evaluated in cocaine CPP as previously described (Sanjakdar et al., 2015; Zachariou et al., 2001 ). In Fig. 3C robust preferences for cocaine (10 mg/kg; i.p.) and nicotine (0.5 mg/ kg; s.c.) were produced after 3 days of conditioning in mice [F (2, 22) ¼ 57.40, p < 0.0001]. The 10 mg/kg dose of cocaine has been previously shown to produce a significant preference in the CPP test (Alajaji et al., 2016; Ignatowska-Jankowska et al., 2013) . Although WY-14643, with a 15 min pretreatment, totally reduced nicotine reward at 1 mg/kg as previously observed in this study [F (3, 25) ¼ 21.18, p < 0.0001], it had no significant effect on cocaine preference (p > 0.05).
Clinically used PPARa agonist fenofibrate reduced nicotine CPP
We utilized the clinically available PPARa agonist fenofibrate in the nicotine CPP paradigm. As previously observed in this study one way ANOVA showed that nicotine induced a significant preference in comparison to saline-treated mice after the 3-day conditioning period (t ¼ 9.883.df ¼ 13;p < 0.05). In Fig. 4 pretreatment with lower doses of fenofibrate (1 and 9 mg/kg) 1 h prior to nicotine did not significantly alter nicotine CPP (p > 0.05). However, the highest Fig. 3 . Effects of PPARa Agonist WY-14643 on Nicotine and Cocaine CPP. Mice were conditioned with either s.c. saline or nicotine (0.5 mg/kg) for 3 days. A robust CPP was observed in nicotine-conditioned mice pre-treated with vehicle. A) Intraperitoneal (i.p.) injection of PPARa agonist WY-14643 (0.3, 0.6, and 1 mg/kg) reduced nicotine reward as measured by the CPP test in a dose-related fashion. B) To evaluate blockade of dose response of nicotine CPP by PPARa agonist mice were conditioned with either saline or nicotine (0.1, 0.5 and 1 mg/kg; s.c.) for 3 days. A robust CPP was observed in nicotine-conditioned mice pre-treated with vehicle by the dose of 0.5 mg/kg or above. Pretreatment with WY-14643 (1 mg/kg; i.p.) reduced nicotine-CPP at the dose of 0.5 and 1 mg/kg nicotine. C) To test the selectivity of the attenuating effect of the PPARa agonist in nicotine CPP a separate group of mice was conditioned by saline, cocaine (10 mg/kg; i.p.) or nicotine (0.5 mg/kg; s.c.) for 3 days. A robust CPP was observed in both nicotine-conditioned and cocaineconditioned mice pre-treated with vehicle. The PPARa agonist WY-14643 (1 mg/kg; i.p.) reduced nicotine reward, but not cocaine reward as measured by the CPP test. * Denotes p < 0.05 from vehicle control; # Denotes p < 0.05 from nicotine control. Each point represents the mean ± SEM of n ¼ 6e8 mice per group. Fig. 4 . Effect of PPARa Agonist Fenofibrate on Nicotine CPP. Mice were conditioned with either s.c. saline or nicotine (0.5 mg/kg) for 3 days. A robust CPP was observed in nicotine-conditioned mice pre-treated with vehicle. Fenofibrate (1, 9 and 50 mg/kg; i.p.), clinically used PPARa agonist, reduced nicotine reward as measured by the CPP test in a dose-related fashion. * Denotes p < 0.05 from vehicle control; # Denotes p < 0.05 from nicotine control. Each point represents the mean ± SEM of n ¼ 6e8 mice per group. dose of 50 mg/kg of fenofibrate reduced nicotine preference significantly [F (3, 24) ¼ 3.652, p ¼ 0.0267]. Fenofibrate had no effect on its own in saline treated-mice (t ¼ 0.5570, df ¼ 11, p > 0.05). Fenofibrate was administered at doses previously described (Blednov et al., 2016a (Blednov et al., , 2016b .
Nicotine withdrawal signs attenuated by PPARa agonist WY-14643
The physical (somatic signs and hyperalgesia) and affective (anxiety-related behavior) signs of nicotine withdrawal were measured in mice following pretreatment with either WY-14643 or vehicle 15 min prior to mecamylamine administration on day 15. In Fig. 5 nicotine withdrawn mice had a significantly increased anxiety-related behavior in the plus maze (t ¼ 5.469,df ¼ 11,p < 0.05; Fig. 5A ), increased expression of somatic withdrawal signs (t ¼ 6.801,df ¼ 12,p < 0.05; Fig. 5B ) and decreased response latencies in the hot-plate test (t ¼ 3.047, df ¼ 12, p < 0.05; 
Fenofibrate modestly attenuated nicotine withdrawal
Fenofibrate was administered 1 h prior to mecamylamine on day 15 after 14 days of continuous nicotine exposure via osmotic minipumps. Following mecamylamine administration nicotine withdrawals signs (anxiety-like behavior, somatic signs and hyperalgesia) were measured in mice. In Fig. 6 nicotine withdrawn mice displayed an increase in anxiety-related behavior in the plus maze (t ¼ 7.813, df ¼ 14,p < 0.05; Fig. 6A ), enhanced expression of somatic withdrawal signs (t ¼ 12.94,df ¼ 14,p < 0.05; Fig. 6B )and attenuated response latencies in the hot-plate test (t ¼ 5.921, df ¼ 14, p < 0.05; Fig. 6C ) in comparison to their saline minipump- 
Treatment
Average number of arm crosses ±SEM Saline MP-vehicle 7.8 ± 0.9 Saline MP-WY-14643 (5) 8 ± 0.8 Nicotine MP-vehicle 7.1 ± 0.4 Nicotine MP-WY-14643 (0.3) 7.2 ± 0.3 Nicotine MP-WY-14643 (1) 7.2 ± 0.3 Nicotine MP-WY-14643 (5) 7.7 ± 0.5 implanted counterparts. In Fig. 6A one way ANOVA revealed that pretreatment with fenofibrate had no effect on anxiety-like behavior (time in open arms in the plus-maze test) at both doses tested (50 and 100 mg/kg) [F (2, 21) ¼ 1.089, p ¼ 0.3547]. As shown in Table 2 fenofibrate did not significantly alter the number of arm crosses in the plus maze test [F (5, 42) 
However, as shown in Fig. 6B pretreatment with fenofibrate partially attenuated nicotinic somatic withdrawal signs only at the highest dose used of 100 mg/kg [F (2, 21) ¼ 6.928, p ¼ 0.0049]. Somatic signs were expressed in the following distribution: paw tremors (~70%), body tremors (~5%), head shakes (~10%), backing (~15%). Fenofibrate partially attenuated these individual somatic signs in a uniformed manner. Lastly, as shown in Fig. 6C pretreatment with fenofibrate was ineffective at attenuating the expression of hyperalgesia (hot-plate latency) at both doses tested [
The highest dose of fenofibrate tested (100 mg/kg) did not significantly affect behavioral responses in saline-infused mice in any withdrawal test. In the nicotine withdrawal studies fenofibrate was administered at doses previously described (Blednov et al., 2016a (Blednov et al., , 2016b .
Discussion
This is the first report demonstrating the ability of a PPARa antagonist to block the inhibitory effects of an a7 nAChR agonist on nicotine reward in a mouse CPP paradigm (Fig. 2) . This suggests that a7 nAChR activation attenuates nicotine CPP in a PPARadependent mechanism. We therefore compared the effects of a selective and potent PPARa agonist, WY-14643, to fenofibrate, a clinically available PPARa agonist in nicotine mouse models of reward and withdrawal. Our results provide some important and novel insights about the effects of PPARa agonists in these nicotine dependence tests. The PPARa agonists WY-14643 and fenofibrate attenuated nicotine preference as expected but fenofibrate was less potent (Figs. 3A and 4) . Also, in contrast to WY-14643, fenofibrate had a modest efficacy in reducing nicotine withdrawal signs (Figs. 5 and 6).
Our results indicated that attenuation by a7 nAChR activation in nicotine CPP is PPARa mediated (Fig. 2) . This finding is consistent with suggestion that an a7 nAChR agonist prevents nicotineinduced excitation of dopamine neurons via PPARa mechanism (Melis et al., 2013) . Indeed, the PPARa agonist WY-14643 completely and dose-dependently blocked nicotine conditioned reward in the CPP test (Fig. 3A) . In addition, WY-14643 at the highest effective dose (1 mg/kg) blocked all doses of nicotine in the CPP test (Fig. 3B) . Furthermore, WY-14643 (1 mg/kg) had no significant effect on cocaine CPP suggesting behavioral selectivity of WY-14643 for attenuating nicotine reward (Fig. 3C) . In support of our findings WY-14643 has been previously shown to be ineffective in reducing cocaine self-administration (Mascia et al., 2011) .Our (50) 7.6 ± 0.5 Saline MP-Fenofibrate (100) 7.4 ± 0.3 Nicotine MP-vehicle 7.1 ± 0.5 Nicotine 7.8 ± 0.5 Nicotine MP-Fenofibrate (100) 8 ± 0.8 findings with WY-14643 are consistent with other PPARa agonists such as clofibrate that was reported to attenuate nicotine reinforcement and reinstatement in rats through a PPARa mechanism of action (Mascia et al., 2011; Muldoon et al., 2013; Panlilio et al., 2012) . Our study with fenofibrate in nicotine CPP showed that fenofibrate blocked the development of nicotine CPP at a lower potency (a 9-fold difference estimate) than WY-14643, the selective and potent PPARa agonist (Fig. 4) . In fact, the dose of fenofibrate to completely block nicotine CPP was 50 mg/kg. At the higher dose of 100 mg/kg, fenofibrate-treated mice were no longer statistically different from the nicotine-treated mice. Our nicotine withdrawal results suggest PPARa activation by WY-14643 is effective at attenuating nicotine withdrawal signs in a mouse model. To our knowledge this is the first study to evaluate PPARa agonists in a preclinical test for nicotine withdrawal. WY-14643 attenuated both the affective (anxiety-like behavior) and physical (somatic and hyperalgesia) signs of withdrawal (Fig. 5 ) whereas fenofibrate only partially and modestly reduced the somatic signs intensity at the highest dose used, 100 mg/kg (Fig. 6 ). Higher doses of fenofibrate were not investigated due to adverse locomotor effects (data not shown). Clinically available smoking cessation therapies act to a large extent by reducing the nicotine withdrawal signs/symptoms (Mooney and Sofuoglu, 2006) , one of the primary causes of high tobacco relapse rates (Le Foll and Goldberg, 2009 ); consequently, our animal studies included a focus on nicotine withdrawal. Somatic signs have shown to contribute less to nicotine-seeking behavior than affective signs (De Biasi and Dani, 2011; Epping-Jordan et al., 1998) ; thus, the modest reduction of somatic signs by fenofibrate may not predict its efficacy as a smoking cessation aid.
The a7 nAChR full agonist PNU282987 used in the CPP studies is selective for the a7 nAChR (Bodnar et al., 2005; Haj os et al., 2005; Taslim and Saeed Dar, 2011) . However, it has been suggested that a7 nAChR activation might indirectly lead to downregulation of b2-nicotinic subunits via PPARa-induced phosphorylation of these subunits (Melis et al., 2013 (Melis et al., , 2010 . Indeed, a7 nAChR pharmacological activation by PNU282987 enhanced the neuronal levels of endogenous PPARa ligands OEA and PEA in the VTA (Melis et al., 2013) . Therefore, PPARa activation by WY-14643 may attenuate nicotine conditioned reward in the CPP test via a similar mechanism leading to a functional downregulation of b2 subunits. b2-containing nAChRs are well known to play an important role in nicotine reward in the CPP test (Walters et al., 2006) .
The lack of reduction of cocaine CPP by PPARa agonist WY-14643 is somewhat surprising if we assume an important role for b2-containing nAChRs in the effect of PPARa activation. Nevertheless, it is possible that this mechanism (i.e. b2-containing nAChR downregulation) may not be involved in cocaine CPP. Unlike nicotine CPP, genetic and pharmacological activation of a7 nAChRs does not alter cocaine preference (Harenza et al., 2014) . It has been reported that cocaine CPP is partially reduced in b2 knockout mice (Zachariou et al., 2001) at 5 mg/kg of cocaine, suggesting that b2-containing nAChRs play a role in cocaine CPP. However, at the higher dose of 10 mg/kg, the dose used in our study, no reduction of cocaine CPP was observed (Zachariou et al., 2001) . Another possibility is the degree of phosphorylation of the b2 subunit may not be sufficient enough to alter cocaine CPP in comparison to a complete genetic ablation of the b2 subunit (b2 knockout mice). Therefore, the proposed mechanism of a7 nAChR activation indirectly downregulating b2-containing nAChRs may not play a role in cocaine CPP. In nicotine withdrawal, it is possible that regulation of b2 nAChR subunits influences the reversal of nicotine withdrawalrelated signs by the PPARa agonist WY-14643. Indeed, b2-containing nAChRs are important for the affective signs of nicotine withdrawal (Jackson et al., 2008 ). In addition, animal studies reported a correlation between the time-course of brain b2-containing nAChRs upregulation and nicotine withdrawal signs (Gould et al., 2014) . Furthermore, nicotine withdrawn smokers have upregulated b2-containing nAChRs (Cosgrove et al., 2010) .
Collectively our preclinical findings on fenofibrate are consistent with its lack of effectiveness seen in a recent clinical study (Perkins et al., 2015) as a smoking cessation aid. That pilot study was a4-week evaluation of fenofibrate using a within-subjects crossover design with nicotine ¼ dependent volunteers (n ¼ 38). Although that experiment had limitations in sample size, duration and used only one dose of fenofibrate, our data suggest that fenofibrate might not be the appropriate PPARa drug to use because it has modest effects on nicotine withdrawal and has been shown to be a weak and non-selective PPARa agonist (EC50 > 10 mM) (Lo Verme et al., 2005; Willson et al., 2000) . Importantly, our data with WY-14643 and those reported with clofibrate (Panlilio et al., 2012) suggests that PPARa is a potential molecular target to evaluate for smoking cessation. Notably, PPARas undergo different structural conformations upon interaction with different ligands and each ligand-receptor conformation may lead to different patterns of gene expression modulation. For example activation of PPARa by WY-14643 and fenofibrate activate different set of genes as well a small set of overlapping genes (Guo et al., 2006) . Therefore, evaluation of more selective and potent PPARa agonists such as LY518674 (>2000-fold more potent and >300-fold more selective than fenofibrate) and PPARa biased agonists such as the selective PPAR modulators (SPPARMS) K-877 (Pemafibrate ® ) (Liu et al., 2015) should be considered. SPPARMS are thought to interact with the large binding pocket of PPARa to induce a different co-factor recruitment, resulting in higher potency and fewer adverse side effects than the original fibrate compounds (Fruchart, 2013) . LY518674 and K-877 are currently in phase II trials with promising results in treating dyslipidemia (Ishibashi et al., 2016; Raza-Iqbal et al., 2015) . These compounds may prove to be more efficacious candidates for smoking cessation therapy; however, preclinical studies are imperative to investigate this hypothesis. In summary, our findings build on the understanding of the underlying mechanism of a7 nAChR activation in nicotine reward. Further investigation needs to be conducted to elucidate the role of PPARa mediation of a7 nAChR in nicotine dependence.
